News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Ascletis Pharma-B (01672.HK) Completes Enrollment in US Phase II Study of Oral Small Molecule GLP-1R Agonist ASC30
Ascletis Pharma-B (01672.HK) announced that enrollment has been completed in its 13-week US Phase II study (NCT07321678) evaluating the oral small molecule GLP-1 receptor (GLP-1R) ...
Reset
Send
The window will close in 5 seconds
Ascletis Pharma-B (01672.HK) Completes Enrollment in US Phase II Study of Oral Small Molecule GLP-1R Agonist ASC30
Close
Recommend
7
Positive
8
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Ascletis Pharma-B (01672.HK)  +0.200 (+1.426%)    Short selling $8.67M; Ratio 13.510%   announced that enrollment has been completed in its 13-week US Phase II study (NCT07321678) evaluating the oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of type 2 diabetes. Type 2 diabetes is the second indication for ASC30 following obesity, its first indication. Topline data from this Phase II study for the treatment of type 2 diabetes are expected to be available in 3Q26. (ec/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.